I am a translational R&D scientist and Scientific Director with over 15 years of experience developing therapies for rare neuromuscular and neurodegenerative disease. My expertise spans RNA-based therapeutics and gene therapy, from early discovery through clinical translation, with hands-on experience across academia and industry.
My technical background includes antisense oligonucleotide (ASO) design and mechanism, exon-skipping and splice-modulation strategies, and translational pharmacology from target validation through IND-enabling studies. My main focus is Duchenne muscular dystrophy. I hold a PhD in Molecular Biology and Pharmacology and a Specialisation in Medical Genetics.
I am a named inventor on a granted gene therapy patent, author of 27+ peer-reviewed publications, and have contributed scientifically to an FDA-approved rare disease therapy. My work combines deep scientific expertise with strategic R&D leadership, and I remain actively hands-on in the science I lead.”
